GLNS advises industrial biotech company Bind-X on Series B funding round

The Munich-based biotech company Bind-X GmbH has raised EUR 10 million in its Series B financing round. The funding was provided by all existing shareholders (High-Tech Gründerfonds and Vantage Value) as well as renowned new investors, namely US-based HG Ventures, the corporate venture arm of The Heritage Group , Saxovent, a Berlin based project developer, K&K I, and Greeneering Invest.

Bind-X is an industrial biotechnology company based in Martinsried near Munich, which specializes in the biological binding of materials. The funds from the Series B round will be used to expand internationally and to prepare further market entries in agriculture, mining, and infrastructure.

GLNS advised Bind-X on all legal aspects of the transaction. The team consisted of corporate lawyers Dr Daniel Gubitz and Max Schuldt.

GLNS has been advising Bind-X since its inception on its Series Seed and Series A financings, and on general corporate matters.

Download Press Release